Intuniv Related Clinical Trials
Efficacy of Intuniv Extended Release as Adjunctive Therapy With Psycho-stimulant on Executive Function in Children With ADHD [Recruiting]
PK/PD Comparison of Guanfacine ER and IR [Active, not recruiting]
Intuniv vs Placebo in the Treatment of Childhood Intermittent Explosive Disorder [Recruiting]
Efficacy and Safety Eval of Guanfacine Hydrochloride in Combination With Psychostimulants in Adults (18-65). [Completed]
Guanfacine for the Treatment of Hyperactivity in Pervasive Developmental Disorder [Completed]
Guanfacine in Children With Tic Disorders [Active, not recruiting]
Open-Label Pilot Study of Guanfacine-Extended Release for the Treatment of Cannabis Dependence [Completed]
Effect of Guanfacine on the Reversal of Opioid-induced Hyperalgesia (OIH) [Recruiting]
Does Guanfacine Attenuate Stress-Induced Drinking? [Recruiting]
Effect of Guanfacine on Opioid-induced Hyperalgesia (OIH) and Tolerance [Recruiting]
Guanfacine Clinical Trial for Smoking Cessation [Recruiting]
Neurobiological Basis of Response to Guanfacine Extended Release in Children and Adolescents With ADHD [Recruiting]
Electrophysiological Effects of Guanfacine Extended Release in Attention Deficit Hyperactivity Disorder (ADHD) [Completed]
Effect of Guanfacine Extended-Release on Attention Deficit Hyperactivity Disorder (ADHD)-Associated Insomnia [Terminated]
Guanfacine Immediate-release Electrocardiogram Results (QTc) Study [Completed]
The Effects of Ketamine and Guanfacine on Working Memory in Healthy Subjects [Completed]
Access to Extended Release Guanfacine HCl for Subjects Who Participated in Studies SPD503-315 or SPD503-316 in Europe [Active, not recruiting]
An fMRI Study of Non-Stimulant Treatment of ADHD [Recruiting]
CRT-Guanfacine for SPD [Recruiting]
Tolerability and Efficacy of AM and PM Once Daily Dosing With Extended-release Guanfacine Hydrochloride in Children 6-12 With Attention-Deficit/Hyperactivity Disorder (ADHD) (The ADHD Tempo Study) [Completed]
Dose-optimization in Adolescents Aged 13-17 Diagnosed With Attention-deficit/Hyperactivity Disorder (ADHD) Using Extended-release Guanfacine HCl [Completed]
Guanfacine for the Treatment of Spatial Neglect and Impaired Vigilance [Completed]
Inuniv and Working Memory [Completed]
Single Versus Combination Medication Treatment for Children With Attention Deficit Hyperactivity Disorder [Recruiting]
Guanfacine Adjunctive Treatment to Atypical Antipsychotics for Cognitive Dysfunction in Schizophrenia [Active, not recruiting]
Efficacy and Safety of Extended-release Guanfacine Hydrochloride in Children and Adolescents Aged 6-17 Years With Attention-Deficit/Hyperactivity Disorder (ADHD) [Completed]
Language-based Learning Skills and Attention Deficit Hyperactivity Disorder (ADHD): Impact of Treatment With Sustained-release Guanfacine [Completed]
Guanfacine to Treat Borderline Personality Disorder [Recruiting]
Guanfacine to Reduce Stress-Induced Cocaine/Alcohol Craving and Relapse [Recruiting]
Modeling Stress-precipitated Smoking Behavior for Medication Development [Recruiting]
Pharmacology of Cognition in Schizotypal Personality Disorder [Recruiting]
SPD503 (Guanfacine Hydrochloride) in ADHD Plus Oppositional Symptoms [Completed]
Maintenance of Efficacy of Extended-Release Guanfacine HCl in Children and Adolescents With Attention-deficit/Hyperactivity Disorder (ADHD) [Completed]
Guanfacine for the Treatment of Post Traumatic Stress Disorder (PTSD) [Completed]
DORADO-AC-EX - A Long-Term Safety Extension Study to the Phase 3 DORADOC-AC Study (Protocol DAR-312) of Darusentan in Resistant Hypertension [Terminated]
DORADO-AC - Optimized Doses of Darusentan as Compared to an Active Control in Resistant Hypertension [Completed]
A Drug Interaction Study of SPD503 and Concerta Administered Alone and In Combination in Normal Healthy Volunteers [Completed]
Stress and Medication Effects on Cocaine Cue Reactivity [Completed]
Interventions for Children With Attention and Reading Disorders [Active, not recruiting]
Efficacy and Safety of SPD503 in Combination With Psychostimulants [Completed]
Phase III Randomized, Double-Blind, Placebo-Controlled Study of Guanfacine for Tourette Syndrome and Attention Deficit Hyperactivity Disorder [Completed]
Treatment of Supine Hypertension in Autonomic Failure [Recruiting]
SPD503 in Subjects Aged 6-17 Years With Generalized Anxiety Disorder (GAD), Separation Anxiety Disorder (SAD), or Social Phobia (SoP) [Completed]
Safety and Efficacy of SPD503 in Treating Attention-Deficit/Hyperactivity Disorder (ADHD) in Children Aged 6-17 [Completed]
A Drug Interaction Study of SPD503 and Vyvanse Administered Alone and In Combination in Normal Healthy Volunteers [Completed]
Safety and Tolerability of SPD503 and Psychostimulants in Children and Adolescents Aged 6-17 With Attention-Deficit/Hyperactivity Disorder (ADHD) [Completed]
Safety, Tolerability and Efficacy of SPD503 in Treating ADHD in Children Aged 6-17 [Completed]
Safety and Efficacy of SPD503 in Treating ADHD in Children and Adolescents Aged 6-17 [Completed]
Methylphenidate in Children and Adolescents With Pervasive Developmental Disorders [Completed]
The Role of Norepinephrine in Emotional Processing [Completed]
Naltrexone and Adrenergic Agents to Reduce Heroin Use in Heroin Addicts [Completed]
Renin-Guided Therapeutics in the Management of Untreated, Uncontrolled, or Complicated Hypertension [Completed]
N-acetylcysteine (NAC) for Children With Tourette Syndrome [Completed]
|